Pediatric relapsed/refractory ALK+ anaplastic large cell lymphoma treatment and outcomes in the targeted drug era.
Marks LJ, Ritter V, Agrusa J, Kamdar KY, Rivers J, Gardner RA, Ehrhardt MJ, Devine KJ, Phillips CA, Reilly AF, August K, Weinstein JL, Satwani P, Forlenza CJ, Smith CM, Greer C, Afify Z, Lin CH, Belsky JA, Ding H, Hoogstra D, Toner K, Link MP, Schultz LM, Lowe EJ, Aftandilian C.
Marks LJ, et al. Among authors: lin ch.
Blood Adv. 2025 Jan 22:bloodadvances.2024014745. doi: 10.1182/bloodadvances.2024014745. Online ahead of print.
Blood Adv. 2025.
PMID: 39841960